Predicting Medication Response for Autoimmune Disease (REEF)

Coral Genomics

Status: Terminated

Conditions: Psoriasis; Ulcerative Colitis; Crohn's Disease; Rheumatoid Arthritis

Treatments: Diagnostic Test: Coral FRS test

Study type: Observational

Funder types: Industry; NIH

Identifiers

NCT04995783

2R44HG010445-02 (U.S. NIH Grant/Contract)

20201349

Details and patient eligibility

About

Coral is conducting a large study comparing and predicting the relative effectiveness of different medications for autoimmune patients.

Patients with Inflammatory Bowel Disease (IBD) who have been diagnosed with either Ulcerative Colitis or Crohn's Disease and are undergoing treatment are eligible to participate.

Patients with Rheumatoid Arthritis (RA) and Psoriasis (Ps) will also be enrolled.

A novel clinical test will be performed to predict the responsiveness of a particular patient to different immune modulating therapies used in these conditions.

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis diagnosis
• On or about to begin a treatment for condition above

Trial design

200 participants in 5 patient groups

Ulcerative Colitis

Treatment:

Diagnostic Test: Coral FRS test

Crohn's Disease

Treatment:

Diagnostic Test: Coral FRS test

Rheumatoid Arthritis

Treatment:

Diagnostic Test: Coral FRS test

Psoriasis

Treatment:

Diagnostic Test: Coral FRS test

Control